Truist Financial’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11M Buy
162,631
+50,484
+45% +$3.36M 0.01% 615
2026
Q1
$7.04M Buy
112,147
+18,734
+20% +$1.3M 0.01% 722
2025
Q4
$6.2M Sell
93,413
-154,509
-62% -$9.99M 0.01% 764
2025
Q3
$16.7M Buy
247,922
+48,993
+25% +$3.88M 0.02% 458
2025
Q2
$17.4M Buy
198,929
+48,763
+32% +$3.82M 0.03% 436
2025
Q1
$10.3M Sell
150,166
-11,365
-7% -$927K 0.02% 554
2024
Q4
$12.6M Sell
161,531
-5,787
-3% -$428K 0.02% 511
2024
Q3
$11.2M Buy
167,318
+123,822
+285% +$10.2M 0.02% 550
2024
Q2
$4.93M Sell
43,496
-8,261
-16% -$1.04M 0.01% 866
2024
Q1
$7.18M Sell
51,757
-240
-0.5% -$30.2K 0.01% 747
2023
Q4
$6.45M Sell
51,997
-24,088
-32% -$2.46M 0.01% 774
2023
Q3
$7.1M Sell
76,085
-5,306
-7% -$598K 0.01% 711
2023
Q2
$10.5M Sell
81,391
-6,258
-7% -$757K 0.02% 571
2023
Q1
$10.2M Sell
87,649
-20,384
-19% -$2.28M 0.02% 590
2022
Q4
$12.2M Sell
108,033
-7,004
-6% -$769K 0.02% 503
2022
Q3
$9.27M Buy
115,037
+2,817
+3% +$239K 0.02% 578
2022
Q2
$8.36M Sell
112,220
-1,156
-1% -$106K 0.02% 628
2022
Q1
$14.5M Buy
113,376
+19,760
+21% +$2.16M 0.02% 524
2021
Q4
$12.6M Buy
93,616
+1,828
+2% +$263K 0.02% 567
2021
Q3
$12.5M Buy
91,788
+1,300
+1% +$164K 0.02% 558
2021
Q2
$9.66M Sell
90,488
-616
-0.7% -$59.2K 0.02% 646
2021
Q1
$8.19M Buy
91,104
+11,408
+14% +$1.07M 0.01% 670
2020
Q4
$7.37M Buy
79,696
+2,468
+3% +$220K 0.01% 688
2020
Q3
$7.96M Buy
77,228
+77,012
+35,654% +$8.05M 0.02% 612
2020
Q2
$22K Sell
216
-69,600
-100% -$6.23M ﹤0.01% 2360
2020
Q1
$4.7M Buy
69,816
+4,988
+8% +$310K 0.01% 697
2019
Q4
$3.55M Buy
+64,828
New +$3.07M 0.01% 888
2017
Q3
Sell
-19,404
Closed -$355K 803
2017
Q2
$355K Sell
19,404
-156
-0.8% -$2.88K 0.01% 633
2017
Q1
$414K Buy
19,560
+4,920
+34% +$96K 0.01% 608
2016
Q4
$218K Buy
14,640
+4,380
+43% +$77.6K ﹤0.01% 774
2016
Q3
$225K Buy
+10,260
New +$228K ﹤0.01% 758

Other funds holding DXCM

Truist Financial's DXCM Position: Q2 2026 in Review

Truist Financial increased its DexCom (DXCM) stake by 45% in Q2 2026, buying an estimated $3.36M and bringing the position to 162,631 shares worth $11M. The position accounts for 0.01% of the portfolio, ranked #615.

Truist Financial first reported a position in DXCM in Q3 2016 and has held it in 31 quarters since. The position peaked at $17.4M in Q2 2025. 444 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Truist Financial held 162,631 shares of DexCom worth $11M as of Q2 2026.
  • Truist Financial bought 50,484 DexCom shares in Q2 2026, an estimated $3.36M.
  • DexCom made up 0.01% of Truist Financial's portfolio in Q2 2026, its #615 holding.
  • Truist Financial first reported a position in DexCom in Q3 2016 and has held it in 31 quarters since.
  • Truist Financial's DexCom position peaked at $17.4M in Q2 2025.
  • 444 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.